On the recordJuly 28, 2009
I might note that this is not a cheap investment.
Source
congress.govI might note that this is not a cheap investment.
Burr discusses the financial implications of addressing the claims backlog.
Share
More from Richard Burr
I think we should all be able to agree, the status quo on childcare is not meeting the needs of our constituents.
More than 278 therapies have been approved under the accelerated approval pathway over the 30 year history, saving and improving thousands of lives.
I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.
Why did FDA agree, and why did the industry agree to longer review times of 128 days on 510(k)'s and provide the agency with so much more money?